(Q35234959)

7 August 2017

1 reference

title

Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? (English)

1 reference

7 August 2017

0 references

1 reference

2

Russell E Ware

1 reference

7 August 2017

Patrick T McGann

1

1 reference

7 August 2017

1 May 2011

1 reference

Current Opinion in Hematology

7 August 2017

1 reference

7 August 2017

18

1 reference

7 August 2017

3

1 reference

7 August 2017

158-165

1 reference

Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

The inherited diseases of hemoglobin are an emerging global health burden

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

How I use hydroxyurea to treat young patients with sickle cell anemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Improved survival of children and adolescents with sickle cell disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea for children with sickle cell disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

The myeloproliferative disorders

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Developmental pattern of splenic dysfunction in sickle cell disorders.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Fetal hemoglobin, sickling, and sickle cell disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Five years of experience with hydroxyurea in children and young adults with sickle cell disease

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181131

Effect of hydroxyurea on ribonucleotide reductase

26 September 2018

1 reference

12 December 2020

Functional asplenia in sickle-cell anemia

1 reference

12 December 2020

Renal abnormalities in sickle cell disease

1 reference

12 December 2020

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

12 December 2020

Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial

1 reference

12 December 2020

Leg ulcers associated with long-term hydroxyurea therapy

1 reference

12 December 2020

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group

1 reference

12 December 2020

PRELIMINARY SURVEY OF HYDROXYUREA (NSC-32065) AS A TERATOGEN

1 reference

12 December 2020

A comparative study of renal concentrating ability in children with sickel cell anemia and in normal children

1 reference

12 December 2020

A case for developing North-South partnerships for research in sickle cell disease

1 reference

12 December 2020

Population estimates of sickle cell disease in the U.S.

1 reference

12 December 2020

Renal abnormalities in sickle cell disease

1 reference

12 December 2020

Metabolic and Therapeutic Effects of Hydroxyurea in Chronic Myeloid Leukemia

1 reference

12 December 2020

10.1097/MOH.0B013E32834521DD

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

PubMed ID

21372708